Novartis (NVS) provides update on Phase III GCAptAIN study of Cosentyx in giant cell arteritis

Novartis (NYSE: NVS) today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).

In the study, Cosentyx was evaluated in combination with a 26-week steroid taper and compared to placebo plus a 52-week steroid taper. Cosentyx did not demonstrate a statistically significant improvement in sustained remission at Week 52 compared to placebo. While the secondary outcomes did not show statistical superiority, Cosentyx showed numerically better outcomes compared to placebo for cumulative steroid dose and steroid-related toxicity1. Safety in GCA was consistent with the known safety profile of Cosentyx1, which is supported by robust evidence and 10 years of real-world data across its approved indications2-7.

“While the Phase III results of GCAptAIN did not replicate the positive outcomes observed in the Phase II trial, we remain committed to continuing to drive scientific progress and deepening the understanding of immune-mediated diseases,” said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer, Novartis. “We are grateful to the patients, investigators, and teams who made this study possible and will continue focusing on addressing areas of unmet medical need.”

Novartis will complete a full evaluation of the GCAptAIN data and share the results at a later date.

You May Also Be Interested In

• Heartflow (HTFL) Files for Proposed IPO
• Western Alliance Bancorporation (WAL) Appoints Vishal Idnani as CFO effective January 2, 2026
• WonderFi shareholdrs Approve Acquisition by Robinhood